{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:02:38Z","timestamp":1778961758979,"version":"3.51.4"},"reference-count":49,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2019,11,2]]},"DOI":"10.1080\/14712598.2019.1659777","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T11:34:58Z","timestamp":1566992098000},"page":"1119-1126","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Pembrolizumab for the treatment of diffuse large B-cell lymphoma"],"prefix":"10.1080","volume":"19","author":[{"given":"Semira","family":"Sheikh","sequence":"first","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"CIT0001","unstructured":"NCI. [cited 2019 Mar 20]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. 2019"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15412"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.9593"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802108870"},{"key":"CIT0005","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow SH","year":"2017","edition":"4"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0231"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.011"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.2596"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05603.x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.11.013"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750174"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786988"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056"},{"key":"CIT0016","volume":"130","author":"Sehn LH","year":"2017","journal-title":"Blood"},{"key":"CIT0017","volume":"126","author":"Ward JP","year":"2015","journal-title":"Blood"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012534"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00351"},{"key":"CIT0025","unstructured":"FDA. 2018 [cited 2019 July 7]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-treatment-relapsed-or-refractory-pmbcl"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-740993"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879015"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"CIT0029","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3074.3074","volume":"124","author":"Arcari A","year":"2014","journal-title":"Blood"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0137"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12788"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673236"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1002\/path.4522"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.985673"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-014-1615-5"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629600"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1111\/his.12882"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1038\/nature18294"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150656"},{"key":"CIT0041","unstructured":"MERCK. Highlights of prescribing information. KEYTRUDA\u00ae (pembrolizumab) for injection, for intravenous use. 2018."},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383"},{"key":"CIT0043","volume-title":"Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 studies","author":"Armand P","year":"2018"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685"},{"key":"CIT0045","first-page":"4121","volume":"130","author":"Chong EA","year":"2017","journal-title":"Blood"},{"key":"CIT0046","volume-title":"PD-1 blockade with pembrolizumab for classical Hodgkin Lymphoma after autologous stem cell transplant","author":"Armand P","year":"2018"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764209"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2019.1659777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T03:44:27Z","timestamp":1597635867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2019.1659777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,2]]}},"alternative-id":["10.1080\/14712598.2019.1659777"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2019.1659777","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}